Evolus Inc (EOLS) Actualités

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Evolus Reports Third Quarter 2024 Results

Total Net Revenue of $61.1 Million for Q3 2024, Up 22% from Q3 2023; Year-To-Date Growth of 33% Received Approval for Estyme® Injectable...

Evolus to Participate in Stifel 2024 Healthcare Conference

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its...

Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the...

Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers

Achieves 2 Million Jeuveau® Redemptions Anticipates Launch of Club Evolus™, the first consumer membership program by a neurotoxin manufacturer...

Evolus to Report Third Quarter Financial Results on November 6, 2024

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced...

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the...

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the...

Form 4 - Statement of changes in beneficial ownership of securities

Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced the company will be...

Form 4 - Statement of changes in beneficial ownership of securities

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the...